Published in Ann Oncol on February 29, 2012
Personalized Cancer Therapy for Patients With Metastatic Medullary Thyroid Cancer | NCT02363647
Nomogram to predict cycle-one serious drug-related toxicity in phase I oncology trials. J Clin Oncol (2014) 3.57
Doxycycline reverses epithelial-to-mesenchymal transition and suppresses the proliferation and metastasis of lung cancer cells. Oncotarget (2015) 0.92
Learning from toxicity patterns in phase I trials during the era of mechanism targeted agents. Ann Oncol (2012) 0.79
Randomized phase II trial of sorafenib alone or in combination with carboplatin/paclitaxel in women with recurrent platinum sensitive epithelial ovarian, peritoneal, or fallopian tube cancer. Invest New Drugs (2014) 0.78
The role of age on dose-limiting toxicities in phase I dose-escalation trials. Clin Cancer Res (2014) 0.78
Incidence of infusion reactions to anti-neoplastic agents in early phase clinical trials: The MD Anderson Cancer Center experience. Invest New Drugs (2016) 0.75
Quality-of-Life (QOL) during Screening for Phase 1 Trial Studies in Patients with Advanced Solid Tumors and Its Impact on Risk for Serious Adverse Events. Cancers (Basel) (2017) 0.75
Toxicity and response criteria of the Eastern Cooperative Oncology Group. Am J Clin Oncol (1982) 43.81
Risks and benefits of phase 1 oncology trials, 1991 through 2002. N Engl J Med (2005) 8.25
Trends in the risks and benefits to patients with cancer participating in phase 1 clinical trials. JAMA (2004) 4.36
Cancer: the road to Amiens. J Clin Oncol (2008) 3.10
Risks and benefits of phase 1 oncology trials, revisited. N Engl J Med (2005) 2.98
Phase I oncology studies: evidence that in the era of targeted therapies patients on lower doses do not fare worse. Clin Cancer Res (2010) 2.56
Clinical outcome and prognostic factors for patients treated within the context of a phase I study: the Royal Marsden Hospital experience. Br J Cancer (2008) 2.35
Ethics of phase 1 oncology studies: reexamining the arguments and data. JAMA (2003) 2.28
Multivariable analysis of prognostic factors for toxicity and survival for patients enrolled in phase I clinical trials. Ann Oncol (2000) 2.20
Equipoise lost: ethics, costs, and the regulation of cancer clinical research. J Clin Oncol (2010) 2.16
Prospective validation of a prognostic score to improve patient selection for oncology phase I trials. J Clin Oncol (2009) 2.11
Therapeutic response in phase I trials of antineoplastic agents. Cancer Treat Rep (1986) 1.91
Response rates, duration of response, and dose response effects in phase I studies of antineoplastics. Invest New Drugs (1991) 1.67
Responses and toxic deaths in phase I clinical trials. Ann Oncol (1990) 1.43
Bevacizumab toxicities and their management in ovarian cancer. Gynecol Oncol (2010) 1.27
Comparison of prognostic factors in patients in phase I trials of cytotoxic drugs vs new noncytotoxic agents. Br J Cancer (2003) 1.25
Design and results of phase I cancer clinical trials: three-year experience at M.D. Anderson Cancer Center. J Clin Oncol (1996) 1.10
Therapeutic response and potential pitfalls in phase I clinical trials of anticancer agents conducted in Japan. Cancer Chemother Pharmacol (1994) 1.05
Review of the contemporary cytotoxic and biologic combinations available for the treatment of metastatic breast cancer. Clin Ther (2009) 0.96
Combining targeted therapies: practical issues to consider at the bench and bedside. Oncologist (2010) 0.94
Clinical outcomes and factors predicting development of venous thromboembolic complications in patients with advanced refractory cancer in a Phase I Clinic: the M. D. Anderson Cancer Center experience. Am J Hematol (2009) 0.93
The biology of chronic myeloid leukemia. N Engl J Med (1999) 4.80
Biochemistry and pathology of radical-mediated protein oxidation. Biochem J (1997) 3.14
Prognostic impact of discordance between triple-receptor measurements in primary and recurrent breast cancer. Ann Oncol (2009) 2.71
Systemic anticancer therapy in gynecological cancer patients with renal dysfunction. Int J Gynecol Cancer (2007) 2.71
Sputum microscopy results at two and three months predict outcome of tuberculosis treatment. Int J Tuberc Lung Dis (1997) 2.53
Mycosis fungoides and Sezary syndrome. Blood (1996) 2.15
Increased expression of inducible nitric oxide synthase and cyclooxygenase-2 in Barrett's esophagus and associated adenocarcinomas. Cancer Res (1998) 1.94
microRNA-22, downregulated in hepatocellular carcinoma and correlated with prognosis, suppresses cell proliferation and tumourigenicity. Br J Cancer (2010) 1.90
Sweet's syndrome and cancer. Clin Dermatol (1993) 1.88
A precision measurement of the mass of the top quark. Nature (2004) 1.87
Association of sebaceous gland tumors and internal malignancy: the Muir-Torre syndrome. Am J Med (1991) 1.82
Geographic distribution, virologic and clinical characteristics of hepatitis B virus genotypes in China. J Viral Hepat (2005) 1.74
Prognostic value of serum interleukin-6 in diffuse large-cell lymphoma. Ann Intern Med (1997) 1.71
Pilot trial of sunitinib therapy in patients with von Hippel-Lindau disease. Ann Oncol (2011) 1.70
Malignancy-associated Sweet's syndrome: review of the world literature. J Clin Oncol (1988) 1.66
Sweet's syndrome: a neutrophilic dermatosis classically associated with acute onset and fever. Clin Dermatol (2000) 1.62
A novel c-abl protein product in Philadelphia-positive acute lymphoblastic leukaemia. Nature (1987) 1.61
Patterns of electrical propagation in the intact pregnant guinea pig uterus. Am J Physiol Regul Integr Comp Physiol (2007) 1.61
Survival advantage observed with the use of metformin in patients with type II diabetes and colorectal cancer. Br J Cancer (2012) 1.61
Myelomatous effusion with poor response to chemotherapy. J Korean Med Sci (2000) 1.60
Measurement of the forward-backward charge asymmetry in top-quark pair production. Phys Rev Lett (2008) 1.53
Serum levels of interleukin-10 in patients with diffuse large cell lymphoma: lack of correlation with prognosis. Blood (1995) 1.52
Clinical toxicity of interferons in cancer patients: a review. J Clin Oncol (1986) 1.50
Selective hepatic vascular exclusion versus Pringle manoeuvre in liver resection for tumours encroaching on major hepatic veins. Br J Surg (2012) 1.47
Expression of p21ras in fresh primary and metastatic human colorectal tumors. Proc Natl Acad Sci U S A (1985) 1.47
Stable markers of oxidant damage to proteins and their application in the study of human disease. Free Radic Biol Med (1999) 1.45
Subcellular localization of Bcr, Abl, and Bcr-Abl proteins in normal and leukemic cells and correlation of expression with myeloid differentiation. J Clin Invest (1993) 1.43
Interleukin-6 and interleukin-10 levels in chronic lymphocytic leukemia: correlation with phenotypic characteristics and outcome. Blood (2001) 1.43
An upper limit on the stochastic gravitational-wave background of cosmological origin. Nature (2009) 1.42
The human cellular abl gene product in the chronic myelogenous leukemia cell line K562 has an associated tyrosine protein kinase activity. Virology (1985) 1.41
Chronic myelogenous leukemia: a concise update. Blood (1993) 1.40
Herpes simplex virus infections and cimetidine therapy. J Am Acad Dermatol (1988) 1.39
Sweet syndrome in patients with solid tumors. Cancer (1993) 1.38
Is the Wii Fit a new-generation tool for improving balance, health and well-being? A pilot study. Climacteric (2010) 1.37
A phase I trial of intravenously-administered recombinant tumor necrosis factor-alpha in cancer patients. J Clin Oncol (1988) 1.36
Immunophenotype and molecular characterisation of adenocarcinoma of the small intestine. Br J Cancer (2009) 1.32
Serum interleukin-6 levels correlate with prognosis in diffuse large-cell lymphoma. J Clin Oncol (1995) 1.30
Protein hydroperoxides can give rise to reactive free radicals. Biochem J (1995) 1.30
The Saccharomyces cerevisiae TCM62 gene encodes a chaperone necessary for the assembly of the mitochondrial succinate dehydrogenase (complex II). J Biol Chem (1998) 1.28
Interferon-alpha produces sustained cytogenetic responses in chronic myelogenous leukemia. Philadelphia chromosome-positive patients. Ann Intern Med (1991) 1.28
Tripe palms and malignancy. J Clin Oncol (1989) 1.27
Transformation of mycosis fungoides/Sezary syndrome: clinical characteristics and prognosis. Blood (1998) 1.24
BRAF mutant gastrointestinal stromal tumor: first report of regression with BRAF inhibitor dabrafenib (GSK2118436) and whole exomic sequencing for analysis of acquired resistance. Oncotarget (2013) 1.20
Sweet's syndrome and malignancy. Am J Med (1987) 1.18
Systemic chemotherapy and surgical cytoreduction for poorly differentiated and signet ring cell adenocarcinomas of the appendix. Ann Oncol (2011) 1.18
Identification of molecular variants of p210bcr-abl in chronic myelogenous leukemia. Blood (1987) 1.18
A new familial immunodeficiency disorder characterized by severe neutropenia, a defective marrow release mechanism, and hypogammaglobulinemia. Am J Med (1990) 1.17
Muir-Torre syndrome. Dermatol Clin (1995) 1.17
2-chlorodeoxyadenosine induces durable remissions and prolonged suppression of CD4+ lymphocyte counts in patients with hairy cell leukemia. Blood (1994) 1.14
Expression of the macrophage colony-stimulating factor and its receptor in gynecologic malignancies. Cancer (1991) 1.11
Effects of basic fibroblast growth factor (bFGF) on early stages of tendon healing: a rat patellar tendon model. Acta Orthop Scand (2000) 1.11
Upper limits on a stochastic background of gravitational waves. Phys Rev Lett (2005) 1.11
Pharmacokinetics, single-dose tolerance, and biological activity of recombinant gamma-interferon in cancer patients. Cancer Res (1985) 1.10
Measurement of the electron charge asymmetry in pp[over ]-->W+X-->enu+X events at sqrt[s]=1.96 TeV. Phys Rev Lett (2008) 1.09
Safety, tolerability, pharmacokinetics and pharmacodynamics of AZD8055 in advanced solid tumours and lymphoma. Br J Cancer (2012) 1.09
RAS and leukemia: from basic mechanisms to gene-directed therapy. J Clin Oncol (1999) 1.09
Resistance to taxol chemotherapy produced in mouse marrow cells by safety-modified retroviruses containing a human MDR-1 transcription unit. Gene Ther (1995) 1.08
Lymphotoxin is an autocrine growth factor for Epstein-Barr virus-infected B cell lines. J Exp Med (1993) 1.08
Diamond from the dabie shan metamorphic rocks and its implication for tectonic setting. Science (1992) 1.06
Insulin growth factor receptor (IGF-1R) antibody cixutumumab combined with the mTOR inhibitor temsirolimus in patients with metastatic adrenocortical carcinoma. Br J Cancer (2013) 1.06
Phenylbutyrate-induced G1 arrest and apoptosis in myeloid leukemia cells: structure-function analysis. Leukemia (1999) 1.05
iNOS expression in human intestinal microvascular endothelial cells inhibits leukocyte adhesion. Am J Physiol (1998) 1.05
Antithymocyte globulin (ATG)-based therapy in patients with myelodysplastic syndromes. Leukemia (2003) 1.05
Hormonal therapy in ovarian cancer. Int J Gynecol Cancer (2007) 1.05
KBM-7, a human myeloid leukemia cell line with double Philadelphia chromosomes lacking normal c-ABL and BCR transcripts. Leukemia (1995) 1.05
BP1, a new homeobox gene, is frequently expressed in acute leukemias. Leukemia (2000) 1.05
Search for large extra dimensions via single photon plus missing energy final states at sqrt s = 1.96 TeV. Phys Rev Lett (2008) 1.04
Differentiation of canine bone marrow cells with hemopoietic characteristics from an adherent stromal cell precursor. Proc Natl Acad Sci U S A (1995) 1.03
High resolution electrical mapping in the gastrointestinal system: initial results. Neurogastroenterol Motil (1996) 1.03
Persistence of dormant leukemic progenitors during interferon-induced remission in chronic myelogenous leukemia. Analysis by polymerase chain reaction of individual colonies. J Clin Invest (1994) 1.03
Acute appendicitis in patients with acute leukemia. Korean J Intern Med (1993) 1.03
In vitro activity of chloroquine, the two enantiomers of chloroquine, desethylchloroquine and pyronaridine against Plasmodium falciparum. Br J Clin Pharmacol (1986) 1.03
Differential expression of p21ras gene products among histological subtypes of fresh primary human lung tumors. Cancer Res (1986) 1.02
Anisotropic propagation in the small intestine. Neurogastroenterol Motil (2002) 1.02
Expression of Fas ligand in arteries of hypercholesterolemic rabbits accelerates atherosclerotic lesion formation. Arterioscler Thromb Vasc Biol (2000) 1.01
Development of systemic lupus erythematosus after interferon therapy for chronic myelogenous leukemia. Cancer (1991) 1.01
Prognostic factor analysis in mycosis fungoides/Sézary syndrome. J Am Acad Dermatol (1999) 0.99
Functional reentry and circus movement arrhythmias in the small intestine of normal and diabetic rats. Am J Physiol Gastrointest Liver Physiol (2011) 0.99
Distribution and characteristics of hepatitis B virus genotype C subgenotypes in China. J Viral Hepat (2007) 0.98
Transformation of chronic lymphocytic leukemia to lymphoma of true histiocytic type. Cancer (1995) 0.98
Interleukin-10 in non-Hodgkin's lymphoma. Leuk Lymphoma (1997) 0.97
Flow velocity of single lymphatic capillaries in human skin. Am J Physiol (1996) 0.97
Lack of X inactivation associated with maternal X isodisomy: evidence for a counting mechanism prior to X inactivation during human embryogenesis. Am J Hum Genet (1996) 0.97
Leukemia-inhibitory factor stimulates breast, kidney and prostate cancer cell proliferation by paracrine and autocrine pathways. Int J Cancer (1996) 0.97
Lymphatic capillary pressure in patients with primary lymphedema. Microvasc Res (1993) 0.96
Electrocardiograms (ECGs) in phase I anticancer drug development: the MD Anderson Cancer Center experience with 8518 ECGs. Ann Oncol (2012) 0.95
Significance of the P210 versus P190 molecular abnormalities in adults with Philadelphia chromosome-positive acute leukemia. Blood (1991) 0.95
Elevated plasma thrombopoietic activity in patients with metastatic cancer-related thrombocytosis. Am J Med (1995) 0.95
Decreased mRNA expression of tight junction proteins in lumbar spinal cords of patients with ALS. Neurology (2009) 0.95
The spatial behaviour of spike patches in the feline gastroduodenal junction in vitro. Neurogastroenterol Motil (2000) 0.94
Biological properties and growth in SCID mice of a new myelogenous leukemia cell line (KBM-5) derived from chronic myelogenous leukemia cells in the blastic phase. Cancer Res (1993) 0.94
Observation of single top-quark production. Phys Rev Lett (2009) 0.94